Long-term neurodevelopmental outcome and brain volume after treatment for hydrops fetalis by in utero intravascular transfusion - 18/08/11
, Hanes M. Swingle, MD a, Carl P. Weiner, MD d, Daniel J. Bonthius, MD, PhD a, b, c, Glen P. Aylward, PhD e, John A. Widness, MD aAbstract |
Objective |
We tested the hypothesis that long-term neurodevelopmental outcomes of successfully treated fetuses with immune hydrops are similar to their unaffected siblings according to a protocol that addresses the underlying pathophysiologic condition.
Study design |
Sixteen of 18 consecutive hydropic fetuses (89%) who were treated in a dedicated fetal medicine unit between July 1985 and October 1995 survived. The transfusion protocol used a 2-step correction over a 2 to 4 day interval, combined with umbilical venous pressure measurements to avoid over transfusion and bicarbonate administration to assure a posttransfusion UV pH of >7.30. Survivors were evaluated at a mean age of 10 years. Statistical analyses included t-test, Wilcoxon rank-sum test, Fisher’s exact test, and Pearson coefficients.
Results |
Overall, death or major neurologic morbidity occurred in 4 of 18 of the fetuses (22%) who were treated (2/16 of survivors [12.5%]). Among the survivors, the children with immune hydrops had physical, neurologic, and cognitive outcomes statistically similar to their siblings, except for a measure of visual attention. Two of the children (12%) had major neurologic sequelae. Brain volumes were statistically smaller than unrelated control subjects by 8.8%, but these control subjects were not matched for height at testing or gestational age at birth. Both groups had brain volumes within the normal range.
Conclusion |
Intravascular transfusion of fetuses with profoundly anemic immune hydrops results in high survival rates and favorable long-term neuropsychological outcomes.
Le texte complet de cet article est disponible en PDF.Key words : Fetus, Anemia, Hemolytic disease, Hydrops, Intrauterine blood transfusion
Plan
| Supported by the General Clinical Research Centers Program, grant NCRR RR00059; the National Institutes of Health, grant P01 HL46925; and the Children’s Miracle Network Telethon of Iowa. |
Vol 195 - N° 1
P. 192-200 - juillet 2006 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
